Degron Therapeutics vs Gilboa Therapeutics
Degron Therapeutics vs Gilboa Therapeutics, compared side by side on 13 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Degron Therapeutics is on 62/100 and Gilboa Therapeutics on 43/100.
Where each one leads
Degron Therapeutics
- our overall score: 62/100 against 43/100
- agent readiness: 27/100 against 22/100
- domain rating: 25/100 against 4/100
- headcount: 24 against 2
- LinkedIn following: 1,380 against 956
Gilboa Therapeutics
Leads on none of the measures we hold for both companies.
At a glance
| Measure | Degron Therapeutics | Gilboa Therapeutics |
|---|---|---|
| What it is | Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines. | Preclinical biopharma developing next-gen cancer immunotherapies using proprietary SolidT technology. |
| Category | Biotechnology, Pharmaceuticals, Drug Discovery, Healthcare | Biopharmaceuticals, Immunotherapy, Cancer Treatment, Biotechnology |
| Sells toBusiness model | B2B | B2G |
| Offering | Platform | Hardware |
| Founded | 2020 | 2017 |
| Headquarters | San Diego, USA | Tel Aviv, Israel |
| Status | Active | Inactive |
Size, funding and growth
| Measure | Degron Therapeutics | Gilboa Therapeutics |
|---|---|---|
| Employees | 24 | 2 |
| Headcount growthLast 12 months | Not published | -49.5% |
| Total funding | $40.0M | Not published |
| Latest round | Series A Extension | Not published |
| Valuation | $1.1B | Not published |
| LinkedIn followers | 1,380 | 956 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Degron Therapeutics | Gilboa Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 62/100 | 43/100 |
| Traction | Not published | 11/100 |
| Team | 24/100 | Not published |
| Search visibility | 57/100 | 54/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (27/100) | F (22/100) |
| Domain ratingLink authority, 0-100 | 25/100 | 4/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Degron Therapeutics | Gilboa Therapeutics |
|---|---|---|
| Hosting | Self Managed | Not detected |
Degron Therapeutics vs Gilboa Therapeutics: common questions
Which is better, Degron Therapeutics or Gilboa Therapeutics?
On our 0-100 score Degron Therapeutics rates higher (62/100 against 43/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 13 data points above: read the rows that match what you are buying for.
How do Degron Therapeutics and Gilboa Therapeutics compare on the numbers?
Degron Therapeutics leads on our overall score (62/100 against 43/100), agent readiness (27/100 against 22/100), domain rating (25/100 against 4/100), headcount (24 against 2), LinkedIn following (1,380 against 956).
Read the full Degron Therapeutics review and pricing or the Gilboa Therapeutics review and pricing. You can also browse other Degron Therapeutics alternatives we track.